Meeting
2013 ASCO Annual Meeting
Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
Authors
Shubham Pant
Stephenson Cancer Center/SCRI, Oklahoma City, OK
Shubham Pant , Lowell L. Hart , Johanna C. Bendell , Jeffrey R. Infante , Suzanne Fields Jones , Adil Mohyuddin , Patrick Murphy , Jeffrey Patton , William Charles Penley , Dana Shelton Thompson , Howard A. Burris III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01226732
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3564)
DOI
10.1200/jco.2013.31.15_suppl.3564
Abstract #
3564
Poster Bd #
4F
Abstract Disclosures
Similar Posters
Poster
2013 Gastrointestinal Cancers Symposium
Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
First Author: Johanna Bendell
Poster
2013 ASCO Annual Meeting
Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.
First Author: Suzanne Fields Jones
Poster
2017 ASCO Annual Meeting
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in advanced solid tumors.
First Author: Noriko Yanagitani
Poster
2016 Gastrointestinal Cancers Symposium
A phase I study of veliparib (ABT-888) in combination with capecitabine (C) and temozolomide (T) in patients (pts) with advanced well-differentiated unresectable neuroendocrine tumors (wdNET).
First Author: Ramya Thota